Comparing the current results to its competitors, Verastem Inc reported Revenue increase in the 1 quarter 2026 by 0 % year on year. The revenue growth was below Verastem Inc 's competitors' average revenue growth of 4.95 %, achieved in the same quarter.
Verastem Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancements and intense competition. It faces potential competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions. Competitors may possess greater financial resources and expertise in areas such as research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Additionally, competitors vie for qualified personnel, clinical trial site establishment, patient registration, and acquisition of complementary technologies. Smaller or early-stage companies may also present significant competition, particularly through collaborations with larger companies. Pfizer is identified as a competitor in company filings.
July 12, 2025
: The article details the primary results from the Phase 2 RAMP 201 clinical trial of avutometinib in combination with defactinib, as recently published by Verastem Oncology in the Journal of Clinical Oncology. The research focuses on recurrent low-grade serous ovarian cancer, a subset of ovarian cancer characterized by its unique clinical course and challenges in treatment. This article elucidates the trial outcomes, underlining the effectiveness of this targeted therapy in patients suffering from this condition.Ovarian cancer remains a significant health concern, with low-grade serous ovarian carcinoma (LGSOC) representing a distinct clinical and molecular entity characterized by its indolence and lower re...
January 2, 2025
The landscape of cancer treatment is continually evolving, driven by innovative research and breakthroughs in drug development. Among the forefront companies leading this charge is Verastem Oncology, which has recently garnered significant attention due to its promising advancements targeting low-grade serous ovarian cancer (LGSOC) characterized by KRAS mutations. In this article, we analyze Verastem s New Drug Application (NDA) for Avutometinib in conjunction with Defactinib, its implications for patient care, and the company s recent financial performance in the competitive biopharmaceutical market. Verastem’s Therapeutic Approach: Avutometinib and Defactinib Overview of Avutometinib and DefactinibAvuto...
December 30, 2024
Beating the Odds: Verastem Oncology s Bold Leap Towards a Groundbreaking Ovarian Cancer Treatment In an era where medical breakthroughs continually reshape the landscape of oncology, one small biopharmaceutical company is daring to challenge the status quo. Boston-based Verastem Oncology (Nasdaq: VSTM) has stepped into the limelight with a promising new development: the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for avutometinib in combination with defactinib for priority review. This duo, an oral RAF/MEK clamp partnered with an oral FAK inhibitor, holds the potential to treat adult patients grappling with recurrent low-grade serous ovarian cancer (LGSOC), particularl...
October 9, 2024
Verastem Oncology, a committed biopharmaceutical entity focused on advancing innovative cancer therapies, has recently made significant strides in the ongoing fight against cancer. The company has announced upcoming details for the oral presentation of its mature data from the RAMP 201 clinical trial, specifically evaluating the combination of two promising treatments avutometinib and defactinib targeting recurrent low-grade serous ovarian cancer. Additionally, the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the same combination for the treatment of pancreatic cancer, marking another significant accomplishment in Verastem’s burgeoning portfolio. RAMP 201 Clinical Tr...
July 30, 2024
Verastem Oncology s Recent Breakthroughs Propelling Innovation in Pancreatic Cancer Treatment Boston - In a significant stride toward improving treatment options for pancreatic cancer, Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to developing advanced medicines for cancer patients, has made noteworthy announcements that signal both clinical and market advancements. FDA Orphan Drug DesignationVerastem announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its novel therapeutic combination of avutometinib and defactinib. This designation specifically targets the treatment of pancreatic cancer, a form of the disease known for its exc...
July 29, 2024
In a significant development for pancreatic cancer treatment, Verastem Oncology announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational therapy consisting of avutometinib and defactinib. Avutometinib is classified as a RAF/MEK clamp, while defactinib is recognized as a selective FAK (Focal Adhesion Kinase) inhibitor. This designation is aimed specifically at addressing the unmet medical needs of patients suffering from pancreatic cancer, a condition known for its low survival rates and limited treatment options.The announcement signals a promising advancement in the therapeutic landscape for pancreatic cancer. The combination therapy of avut...
July 1, 2024
BOSTON July 1, 2024 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new medicines for patients with cancer, has announced pivotal achievements that underscore its commitment to cancer research and its expanding influence in the biopharmaceutical sector. Inclusion in the Russell 3000 and Russell Microcap Indexes In a significant recognition of its recent progress and growing market footprint, Verastem Oncology will be added to the Russell 3000 and Russell Microcap Indexes, effective at the open of U.S. equity markets today, Monday, July 1, 2024. This inclusion is part of the 2024 Russell U.S. Indexes annual reconstitution.Russell Indexes are widely regarded benchmark...
May 28, 2024
Pomerantz Law Firm Sets Sights on Verastem, Inc. Amid Investor Concerns New York, May 28, 2024: In a significant development that has captured the attention of investors and legal analysts alike, Pomerantz LLP has announced an investigation into potential claims on behalf of investors of Verastem, Inc. (NASDAQ: VSTM). This probe, spearheaded by one of the nation s most reputable law firms specializing in securities litigation, seeks to examine whether Verastem, Inc. and its executives have potentially violated federal securities laws, thereby failing to safeguard the interests of their shareholders.Pomerantz LLP, acclaimed for its robust advocacy in investor rights, revealed the investigation through a pre...
May 24, 2024
Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial in Metastatic Pancreatic CancerBOSTON Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing novel therapies for cancer patients, has unveiled promising initial interim safety and efficacy results from its ongoing RAMP 205 Phase 1/2 clinical trial. This trial evaluates the combination of avutometinib and defactinib in conjunction with gemcitabine and nab-paclitaxel as a first-line treatment for patients with metastatic pancreatic cancer. As of the most recent data cutoff on May 14, 2024, the early results demonstrate a favorable safety profile alongside encouraging anti-tumor activity.The RAMP 205 trial ...
Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.
Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.
Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.
Sources:
Verastem Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Verastem Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
